跳至主要内容
临床试验/NCT06917651
NCT06917651招募中3 期

Management of Moderate to Severe Monotraumatic Pain With Sublingual Sufentanil in an Emergency Situation.

University Hospital, Clermont-Ferrand1 个研究点 分布在 1 个国家目标入组 300 人开始时间: 2025年4月22日最近更新:
适应症
干预措施
相关药物

试验速览

阶段
3 期
状态
招募中
发起方
入组人数
300
试验地点
1
主要终点
To determine the effectiveness of sublingual sufentanil compared to the standard analgesic protocol used in the department, by measuring pain scores on the Numerical Rating Scale from 0 to 10 at Hour 0 and Hour 0 +60 minutes

研究概览

简要总结

Pain is a common reason for emergency department (ED) visits. However, studies suggest that emergency physicians may not always provide optimal analgesic treatment due to various factors, such as time constraints, demographic factors like gender and age, and concerns about opioid use. As a result, patients with moderate to severe pain often experience long delays before receiving analgesia and may even be discharged with unresolved pain or suboptimal treatment. Additionally, diagnostic procedures for patients with isolated trauma (e.g., clinical examinations, radiographs) can lead to variations in pain levels, making it difficult to assess the effectiveness of analgesia.

A commonly used treatment for moderate to severe pain is intravenous opioid administration. However, this approach requires longer wait times, complex titration, and significant resources (beds, nurses, equipment), which may be limited during peak hours. While oral opioids require fewer resources, their delayed onset and limited titratability restrict their use for severe pain.

The sublingual sufentanil tablet (30 mcg), delivered via a single-dose applicator, was developed for patients with moderate to severe pain in emergency or outpatient surgical settings. Its unique pharmacokinetic and pharmacodynamic properties could offer advantages in non-invasive acute pain management.

Sublingual sufentanil received market authorization in June 2018 for the treatment of moderate to severe acute pain in adults and is already used in many hospitals. However, further studies are needed to confirm its effectiveness and potential superiority in pain management.

The objective of this study is to evaluate the effectiveness of 30 mcg sublingual sufentanil in patients admitted for moderate to severe pain due to isolated trauma. This will be compared to the standard pain management protocol used in the Clermont-Ferrand emergency department, focusing on pain score variations using a numerical rating scale (0-10)

研究设计

研究类型
Interventional
分配方式
Randomized
干预模型
Parallel
主要目的
Treatment
盲法
None

入排标准

年龄范围
18 Years 至 —(Adult, Older Adult)
性别
All
接受健康志愿者
否

入选标准

  • •Adult patient
  • •Patient with a pain rating on the Numerical Rating Scale (NRS) ≥ 4
  • •Pain of monotraumatic origin in the upper or lower limb
  • •Glasgow Coma Scale = 15
  • •SaO2 > 95% in ambient air

排除标准

  • •Polytrauma
  • •Analgesic treatment within the 4 hours preceding admission (except paracetamol)
  • •Woman of childbearing age without effective contraception, declaring pregnancy or at risk of pregnancy, breastfeeding woman, or positive pregnancy test at inclusion
  • •Patient requiring intravenous access upon admission (e.g., displaced open fracture)
  • •Contraindication or allergy to any of the molecules in the analgesia protocol
  • •Refusal to participate
  • •Known substance abuse or psychiatric disorders
  • •Known oxygen dependence or COPD
  • •Not affiliated with social security
  • •Patient under guardianship, curatorship, deprived of liberty, or under legal protection
  • •Patient who does not speak or read French

研究组 & 干预措施

Standard of Care

Active Comparator

Patient randomized to the "standard of care" arm will receive analgesic treatment according to the department's internal pain management protocol.

干预措施: Standard of Care (SOC) (Other)

SST 30 mcg

Experimental

Patients randomized to the "SST 30 mcg" arm will receive a 30-microgram sublingual sufentanil tablet.

干预措施: sufentanil sublingual 30 mcg tablet (Drug)

结局指标

主要结局

To determine the effectiveness of sublingual sufentanil compared to the standard analgesic protocol used in the department, by measuring pain scores on the Numerical Rating Scale from 0 to 10 at Hour 0 and Hour 0 +60 minutes

时间窗: Hour 0 ; Hour 0 + 60 minutes

the efficacy of sublingual sufentanil will be measured by the difference in pain scores measured by the NRS between baseline and 60 minutes after receiving treatment NRS is a 10-point scale where 0 means no pain and 10 means the most pain

次要结局

  • Oxygen saturation variation(Hour 0 ; Hour 0 + 15 minutes; Hour 0 + 30 minutes; Hour 0 + 45 minutes; Hour 0 + 60 minutes; Hour 0 +120 minutes; Hour 0 + 180 minutes)
  • Breath frequency variations(Hour 0 ; Hour 0 + 15 minutes; Hour 0 + 30 minutes; Hour 0 + 45 minutes; Hour 0 + 60 minutes; Hour 0 +120 minutes; Hour 0 + 180 minutes)
  • Assessment of patient satisfaction with pain management using a 10-point scale(Hour 0 + 180 minutes)
  • Heart rate variations(Hour 0 ; Hour 0 + 15 minutes; Hour 0 + 30 minutes; Hour 0 + 45 minutes; Hour 0 + 60 minutes; Hour 0 +120 minutes; Hour 0 + 180 minutes)
  • Comparison between randomization groups of potential adverse effects.(Hour 0 ; Hour 0 + 15 minutes; Hour 0 + 30 minutes; Hour 0 + 45 minutes; Hour 0 + 60 minutes; Hour 0 +120 minutes; Hour 0 + 180 minutes)
  • Pain variation assessed at different time points.(Hour 0 ; Hour 0 + 15 minutes; Hour 0 + 30 minutes; Hour 0 + 45 minutes; Hour 0 + 60 minutes; Hour 0 +120 minutes; Hour 0 + 180 minutes)
  • Blood pressure variations(Hour 0 ; Hour 0 + 15 minutes; Hour 0 + 30 minutes; Hour 0 + 45 minutes; Hour 0 + 60 minutes; Hour 0 +120 minutes; Hour 0 + 180 minutes)

研究者

发起方
University Hospital, Clermont-Ferrand
申办方类型
Other
责任方
Sponsor

研究点 (1)

Loading locations...

相似试验

Management of Moderate to Severe Monotraumatic Pain... | 临床试验